News | News By Subject | News by Disease News By Date | Search News

Myelodysplastic syndrome News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Shire (SHPG) Pays CTI BioPharma $10.3 Million to Terminate Cancer Deal it Picked Up From Baxalta (BXLT)     10/25/2016
Baxalta (BXLT) Kills Cancer Drug Development Deal With Onconova (ONTX)     3/4/2016
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Onconova Therapeutics Inc. (ONTX) Tanks Following Disappointing Phase 3 Rigosertib Results     2/21/2014
UK Cost Body Endorses Celgene (CELG) Blood Cancer Drug     2/17/2011
FDA Approves Eisai Inc. (ESALF.PK)'s Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)     3/12/2010
SuperGen, Inc. (SUPG) (JOBS) Drug Dacogen Fails Trial; Likely Delay to European Nod     7/2/2008
Eisai Corporation of North America Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes     7/2/2008
Study of Celgene Corporation (CELG)'s VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival     6/3/2008
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) Announces Publication of Clinical Results Underscores VELCADE(R) for Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients     3/13/2008
Celgene (CELG) European Panel Recommends Against Revlimid for MDS     1/25/2008
Pharmion Corporation (PHRM) Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)     1/14/2008
Pharmion Corporation (PHRM) and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study     12/11/2007
Pharmion Corporation (PHRM) (Jobs) Drug Vidaza Extends Life; Shares Soar     8/2/2007

News from Around the Web

Press Releases
Phase 1 Data For Flotetuzumab, MacroGenics (MGNX)’ CD123 X CD3 DART Molecule, Presented At ESMO Congress 2017     9/11/2017
Onconova (ONTX) Announces Establishment Of Collaborative Research And Clinical Programs Evaluating Rigosertib In Pediatric “Rasopathies”     7/25/2017
Syros Pharma Publishes Foundational Data Supporting Ongoing Phase II Clinical Trial Of SY-1425 For Genomically Defined AML And MDS Patients     7/21/2017
Onconova (ONTX) Presents Rigosertib Data At The 22nd Congress Of The European Hematology Association In Madrid     6/26/2017
Sunesis (SNSS) Announces Presentation Of Updated Results From Washington University-Sponsored Phase I/Cohort Expansion Trial Of Vosaroxin Plus Azacitidine In Patients With MDS At The European Hematology Association Annual Meeting     6/23/2017
Onconova (ONTX) Announces Positive Phase II Data In Rigosertib Treated Patients With Second-Line Myelodysplastic Syndromes At The ASCO Annual Meeting     6/5/2017
Onconova (ONTX) To Present A Poster Session Relating To Intravenous Rigosertib At The 2017 ASCO Annual Meeting     5/18/2017
Syros Pharma Presents Data At AACR Further Supporting Clinical Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, For Genomically Defined AML And MDS Patients     4/4/2017
FDA Lifts Clinical Hold On Seattle Genetics (SGEN)’ Cancer Drug Trial     3/6/2017
Syros Pharma Presents Data At American Society of Hematology Annual Meeting Further Supporting Clinical Potential Of Its First-In-Class Selective Rara Agonist For Genomically Defined Subsets Of AML And MDS Patients     12/5/2016
Cellerant Therapeutics, Inc. Awarded $1.5 Million SBIR Contract For Development Of Novel Antibody-Based Therapeutic Against IL1RAP     9/26/2016
Syros Pharma Announces First Patient Enrolled In Phase II Clinical Trial Of SY-1425 In Genomically Defined Patients With Acute Myeloid Leukemia Or Myelodysplastic Syndrome     9/22/2016
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes     6/13/2016
Acceleron Pharma And Celgene (CELG) Announce Updated Results From An Ongoing Phase II Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association     6/10/2016
Mylan (MYL) Launches Generic Vidaza Injection     6/2/2016